2 weeks Ago By ABMN Staff
Dai ichi Life Insurance Company Ltd lessened its stake in STERIS plc ( NYSE:STE – Free Report ) by 4.7% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 12,389 shares of the medical equipment provider’s stock after selling 611 shares during the quarter.
Dai ichi Life Insurance Company Ltd’s holdings in STERIS were worth $2,720,000 as of its most recent SEC filing. A number of other hedge funds have also recently modified their holdings of STE. Vanguard Group Inc.
lifted its holdings in STERIS by 0.5% in the fourth quarter. Vanguard Group Inc.
now owns 11,864,606 shares of the medical equipment provider’s stock valued at $2,608,434,000 after acquiring an additional 53,526 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of STERIS by 7.
5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,738,630 shares of the medical equipment provider’s stock valued at $390,880,000 after purchasing an additional 120,616 shares in the last quarter.
Sustainable Growth Advisers LP lifted its stake in shares of STERIS by 23.5% in the 1st quarter. Sustainable Growth Advisers LP now owns 1,485,578 shares of the medical equipment provider’s stock valued at $333,988,000 after purchasing an additional 282,387 shares during the period.
Impax Asset Management Group plc boosted its holdings in STERIS by 29.7% during the second quarter. Impax Asset Management Group plc now owns 1,150,517 shares of the medical equipment provider’s stock worth $251,663,000 after buying an additional 263,383 shares in the last quarter.
Finally, Principal Financial Group Inc. grew its position in STERIS by 0.9% during the second quarter.
Principal Financial Group Inc. now owns 1,017,888 shares of the medical equipment provider’s stock valued at $223,467,000 after buying an additional 8,601 shares during the period. Hedge funds and other institutional investors own 94.
69% of the company’s stock. STERIS Stock Performance NYSE STE opened at $244.83 on Monday.
The company has a debt-to-equity ratio of 0.35, a current ratio of 2.33 and a quick ratio of 1.
49. STERIS plc has a 1-year low of $195.47 and a 1-year high of $248.
24. The company has a market cap of $24.20 billion, a PE ratio of 64.
09 and a beta of 0.83. The stock’s 50 day simple moving average is $234.
02 and its 200-day simple moving average is $225.20. STERIS Increases Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 20th.
Investors of record on Thursday, September 5th will be paid a dividend of $0.57 per share. This represents a $2.
28 annualized dividend and a yield of 0.93%. The ex-dividend date of this dividend is Thursday, September 5th.
This is a boost from STERIS’s previous quarterly dividend of $0.52. STERIS’s dividend payout ratio is currently 59.
69%. Insider Buying and Selling at STERIS In other news, CFO Michael J. Tokich sold 23,332 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th.
The stock was sold at an average price of $247.00, for a total value of $5,763,004.00.
Following the completion of the sale, the chief financial officer now directly owns 42,930 shares in the company, valued at $10,603,710. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website . In other STERIS news, Director Christopher S.
Holland sold 473 shares of the firm’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $239.68, for a total value of $113,368.
64. Following the completion of the sale, the director now directly owns 582 shares of the company’s stock, valued at approximately $139,493.76.
The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink . Also, CFO Michael J. Tokich sold 23,332 shares of the business’s stock in a transaction dated Tuesday, September 10th.
The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00.
Following the transaction, the chief financial officer now directly owns 42,930 shares in the company, valued at approximately $10,603,710. The disclosure for this sale can be found here . 1.
14% of the stock is owned by insiders. Wall Street Analyst Weigh In A number of research analysts have weighed in on the stock. JMP Securities reiterated a “market outperform” rating and issued a $265.
00 price objective on shares of STERIS in a research report on Wednesday, August 7th. StockNews.com upgraded STERIS from a “hold” rating to a “buy” rating in a research report on Tuesday, August 13th.
Needham & Company LLC restated a “hold” rating on shares of STERIS in a research report on Thursday, August 8th. KeyCorp increased their target price on STERIS from $255.00 to $265.
00 and gave the company an “overweight” rating in a research report on Tuesday, September 3rd. Finally, Stephens reissued an “overweight” rating and issued a $260.00 price target on shares of STERIS in a research note on Wednesday, August 7th.
Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, STERIS presently has an average rating of “Moderate Buy” and a consensus target price of $246.00.
Check Out Our Latest Research Report on STE STERIS Company Profile ( Free Report ) STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Read More Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc ( NYSE:STE – Free Report ). Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.
com's FREE daily email newsletter ..
